China's Price Cut Is Worth Half a Point of the IVD Forecast, Not Four

Two numbers that do not sit together

In 2025 the twelve largest in vitro diagnostics companies in the world sold USD 61.5 billion of diagnostic product between them and grew 1.2%, each measured on its own organic or constant-currency basis. The market they sit inside is forecast at 5.74% a year to 2033. The 4.5-point gap is normally closed with one word — China — and the direction of that explanation is right. The size of it is not.

What actually happened in China is not in dispute. Centralised volume-based procurement reset the administered price of a large block of reagents across 2024 and 2025. Roche’s diagnostics sales in China fell 24% for the year while the same division grew 7% at constant exchange rates excluding China. Siemens named centralised volume-based public procurement as the specific cause of a low-double-digit decline in its China diagnostics revenue. bioMerieux grew microbiology 4% including China and 6.3% excluding it. Werfen grew 3.3% organically and 6% excluding Asia. Sysmex cut its fiscal 2025 guidance from JPY 560 billion to JPY 535 billion citing Chinese government procurement policy and US tariffs. Hologic reported lower cytology volume in China.

Six independent companies describing one mechanism in one year is about as strong as secondary confirmation gets. It still does not make that mechanism worth four points of an eight-year compound growth rate, and the arithmetic that shows why is worth walking through, because it relocates the entire risk of the forecast.

What a deflated base year is actually worth in a CAGR

Take the most generous version of the argument available. Suppose the 2025 base of USD 108.0 billion sits 4% below where it would have been had the Chinese price never reset — USD 112.3 billion instead of USD 108.0 billion — and leave 2033 exactly where the forecast puts it, at USD 168.8 billion.

The eight-year compound rate is then 5.22%, not 5.74%. The whole of the Chinese deflation, on an assumption that flatters it, is worth 0.52 of a percentage point.

The reason is structural rather than empirical. A compound growth rate divides an endpoint by a base and takes an eighth root, so a distortion confined to the base year is diluted seven times before it reaches the reader. A price reset can move a growth rate. It cannot move it by four points from one year of the base.

Read the other direction and the same arithmetic is more useful still. A base-year reset does not create value in 2033; it only makes 2025 look smaller. If China’s adjustment reverses rather than laps, the base rises and the compound rate falls, because the endpoint is untouched. That is the opposite of what a reader assumes when they hear “China recovers”.

The market’s actual 2025 growth rate is 2.02%

Run the two pools at their own 2025 rates. The twelve named participants, at 1.2% on USD 61,525 million, add USD 738 million. The stated residual — the Chinese and regional manufacturers, hospital in-house laboratory networks and unlisted specialists that make up 43.03% of the base — at 3.1% on USD 46,475 million, adds USD 1,441 million. Together that is USD 2,179 million on a base of USD 108,000 million: 2.02%.

The report’s own segment build produces 5.65% in 2026. Work backwards through the same two pools, holding the residual at the report’s own 3.1% assumption, and the twelve named participants have to grow 7.57% in 2026 to deliver it — after growing 1.2% in 2025.

That is the number worth arguing about, and it has nothing to do with a lap. Something has to more than sextuple the growth rate of the largest companies in this market in a single year. A price that stops falling does not do that. A price that stops falling restores a comparator; it does not add one test.

What a procurement award actually does to a revenue line

The Jiangxi biochemical alliance awarded 2,314 specifications at an average price reduction of 70%. The sequence since then is documented in provincial award notices and it is methodical: tumour markers and thyroid function across 28 provinces in 2024, cardiac markers under Anhui’s leadership, routine blood, stool and urine reagents under Gansu in 2025, and a testing service brought inside the mechanism for the first time when Jiangsu’s non-invasive prenatal testing award took effect on 1 January 2025.

A manufacturer cannot decline to participate without leaving the province, and cannot participate without accepting the price. That is a level shift in the price of a reagent — a one-time event in the level, and a permanent event in the comparator. The year after the reset reports a growth rate off a lower number whether or not anything additional was sold, which is exactly why it laps.

What our own interviews added

Our primary layer in this market — depth interviews with laboratory directors and procurement staff, a procurement-side survey, and conversations across the diagnostics conference circuit — was not used to size anything. It was used to establish the sequence of a tender, and three points came back consistently enough to be treated as findings rather than anecdotes.

The award is decided before the menu is discussed. A specification sets a floor and the award goes to unit price at that floor, so a wide assay menu is not a bid advantage. That is the inverse of how a laboratory chooses a platform in a negotiated market, and it explains how a company can be strong in European immunochemistry and weak in a Chinese provincial tender without either fact being surprising.

The buyer benefits, and knows it. A 70% reduction in reagent price improves the laboratory’s own economics immediately; the constraint that follows is the reimbursement rate for the test, not the reagent. Every procurement conversation described the reform as a success. That is a durable political fact, and it is the main reason a reversal is not in our base case.

Switching is a validation cost, not a preference. Laboratories described changing an assay in weeks of technologist time and quality documentation rather than in capital. Volume therefore does not move when price moves; only the revenue per test does. Which is the whole reason a price reset cannot be spent twice.

Where the forecast actually comes from

Not from a lap. From mix, and the segment build says so in its own numbers. Immunoassay and clinical chemistry is 39.81% of the base at 4.5% growth; molecular diagnostics is 20.37% of it at 8.5%; point-of-care and rapid diagnostics is 16.20% at 6.0%; haematology, hemostasis and urinalysis is 11.57% at 4.0%. The market compounds at 5.74% because its fastest discipline gains weight — molecular moves from 20.37% of the base to 25.03% of 2033 — and because the first forecast year, at 5.65%, composes upward from there.

That also locates the risk properly. The report’s sensitivity cases are the honest version of this article: molecular at 6.5% instead of 8.5% leaves a 2033 market of USD 162.97 billion and a compound rate of 5.28%; immunoassay and clinical chemistry at 2.5% instead of 4.5% leaves USD 160.05 billion and 5.04%. Both are volume cases. Neither is a China case.

The single largest exposure to the forecast is therefore not the administered price of a Chinese reagent. It is whether PCR and digital PCR, sequencing and oncology molecular diagnostics keep growing at the rates that made molecular 8.5% in the first place.

The question to ask of any 5.74%

Which discipline carries it? If the answer is “the base year”, the forecast contains half a point of arithmetic and four points of hope. If the answer names molecular, point-of-care and a mix shift, then it is a forecast about test volumes, and the China line becomes what it actually is: a comparator that stops distorting. In that reading 2026 will look better than 2025 whether or not a single additional test is run, and the year to judge the market on is 2027 — the first one where nobody gets to blame a base.

Companion analyses in this cluster: Two Diagnostics Businesses, the Same Operating Profit, a Quarter of the Revenue follows the margin side of the same market; The 43 Per Cent of the IVD Market That Files No Accounts sets out what the residual in the base year contains. Both sit under the Global In Vitro Diagnostics (IVD) Market report, 2026-2033, alongside the discipline-level reports on PCR and digital PCR, next-generation sequencing and oncology molecular diagnostics.

About the method

Roughly 70% secondary and 30% primary, stated that way rather than blended into a single voice. The base year is built bottom-up from twelve disclosed IVD lines — USD 61,525 million, 56.97% of the base — plus a stated residual of USD 46,475 million, 43.03%; no published aggregate was used to set the level. The primary layer is used to explain mechanism only: how an award is sequenced, why a menu does not help a tender, what a laboratory actually compares. Every figure in this article traces to a disclosure, and the arithmetic is stated so it can be checked rather than trusted.

Full construction, the disclosure table, the segment build and every sensitivity case sit in the Global In Vitro Diagnostics (IVD) Market report, 2026-2033. Two companion analyses follow from it: Two Diagnostics Businesses, the Same Operating Profit, a Quarter of the Revenue, on why margin in this market is a menu decision, and The 43 Per Cent of the IVD Market That Files No Accounts, on what the stated residual contains.